Regno Unito - inglese - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - phenelzine sulfate - oral tablet - 15mg

Regno Unito - inglese - MHRA (Medicines & Healthcare Products Regulatory Agency)

part viiid drug tariff special order - phenelzine sulfate - oral capsule - 15mg

Regno Unito - inglese - MHRA (Medicines & Healthcare Products Regulatory Agency)

imported - phenelzine sulfate - oral capsule - 15mg

Stati Uniti - inglese - NLM (National Library of Medicine)

bryant ranch prepack - dextroamphetamine saccharate (unii: g83415v073) (dextroamphetamine - unii:tz47u051fi), amphetamine aspartate monohydrate (unii: o1zpv620o4) (amphetamine - unii:ck833kgx7e), dextroamphetamine sulfate (unii: jj768o327n) (dextroamphetamine - unii:tz47u051fi), amphetamine sulfate (unii: 6dpv8nk46s) (amphetamine - unii:ck833kgx7e) - mixed salts of a single entity amphetamine product are indicated for the treatment of attention deficit hyperactivity disorder (adhd) and narcolepsy. a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv® ) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. the symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. for the inattentive type, at least six of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. for the hyperactive-impulsive type, at least six of the fol

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

neon healthcare limited - phenelzine sulfate 25.83mg equivalent to phenelzine 15 mg - film coated tablet - 15 mg - active: phenelzine sulfate 25.83mg equivalent to phenelzine 15 mg excipient: magnesium stearate maize starch mannitol opadry red 20a25096 povidone - for the treatment of major depression. phenelzine sulfate should rarely be the first antidepressant medicine used. rather it is more suitable for use with patients who have failed to respond to the medicines more commonly used for these conditions

Belgio - inglese - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pfizer sa-nv - phenelzine sulfate 25,83 mg - eq. phenelzine 15 mg - film-coated tablet - 15 mg - phenelzine sulfate 25.83 mg - phenelzine

Canada - inglese - Health Canada

searchlight pharma inc - phenelzine (phenelzine sulfate) - tablet - 15mg - phenelzine (phenelzine sulfate) 15mg - monoamine oxidase inhibitors

Stati Uniti - inglese - NLM (National Library of Medicine)

rebel distributors corp - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x), atropine sulfate (unii: 03j5ze7ka5) (atropine - unii:7c0697dr9i), scopolamine hydrobromide (unii: 451ifr0gxb) (scopolamine - unii:dl48g20x8x) - phenobarbital 16.2 mg in 5 ml - fda has classified the following indications as "possibly" effective:  for use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis.  may also be useful as adjunctive therapy in the treatment of duodenal ulcer.  it has not been shown conclusively whether anticholinergic/antispasmodic drugs aid in the healing of a duodenal ulcer, decrease the rate of recurrences or prevent complications. quadrapax elixir is contraindicated in patients with known hypersensitivity to any of the ingredients.  phenobarbital is contraindicated in patients with acute intermittent porphyria and in those patients in which phenobarbital produces restlessness and/or excitement. it is also contraindicated in patients with glaucoma, obstructive uropathy; paralytic ileus; myasthenia gravis; intestinal atony; unstable cardiovascular status in acute hemorrhage; hiatal hernia associated with reflux esophagitis; obstructive disease of the gastrointestinal tr

Regno Unito - inglese - MHRA (Medicines & Healthcare Products Regulatory Agency)

neon healthcare ltd - phenelzine sulfate - oral tablet - 15mg

Stati Uniti - inglese - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - bupropion hydrochloride (unii: zg7e5poy8o) (bupropion - unii:01zg3tpx31) - bupropion hydrochloride 150 mg - major depressive disorder: bupropion hydrochloride extended-release tablets (xl) are indicated for the treatment of major depressive disorder. the efficacy of bupropion in the treatment of a major depressive episode was established in two 4-week controlled trials of inpatients and in one 6-week controlled trial of outpatients whose diagnoses corresponded most closely to the major depression category of the apa diagnostic and statistical manual (dsm) (see clinical trials). a major depressive episode (dsm-iv) implies the presence of 1) depressed mood or 2) loss of interest or pleasure; in addition, at least 5 of the following symptoms have been present during the same 2-week period and represent a change from previous functioning: depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration,